TRP_1170x120_3-8-19

Pharmaceutical Care Management Association (PCMA)

PCMA makes statement on congressional committee hearings on drug prices 

PCMA makes statement on congressional committee hearings on drug prices 

(Washington, D.C.) — As several congressional committees today examine prescription drug pricing issues Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott released the following statement: “We applaud the Senate Aging Committee, the House Ways and Means Subcommittee on Health, and the House Judiciary Subcommittee on Antitrust, Commercial, and Administrative Law for holding today’s

PCMA launches new advertising campaign

PCMA launches new advertising campaign

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is launching a new print and digital ad campaign – “Protect the Savings” – to defend the savings that pharmacy benefit managers (PBMs) negotiate from drugmakers, and warn against the Administration’s newly proposed regulation that would eliminate these savings for beneficiaries and significantly increases costs to taxpayers. Click

PCMA unveils new campaign on the value of PBMs

PCMA unveils new campaign on the value of PBMs

WASHINGTON— As the debate on prescription drug costs continues and policymakers seek solutions to reduce out-of-control prices for consumers, the Pharmaceutical Care Management Association (PCMA) today is announcing the launch of a new, multi-faceted digital public affairs campaign OnYourRxSide.  The campaign is designed to increase awareness of the value that pharmacy benefit managers (PBMs) bring to patients and the employers and public programs

PCMA comments on administration’s prescription drug rebate proposed rule

PCMA comments on administration’s prescription drug rebate proposed rule

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed rule, we stand ready to work with the Administration to achieve our shared goal

PCMA issues statement on proposal requiring list prices of drugs in TV ads

PCMA issues statement on proposal requiring list prices of drugs in TV ads

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott released the following statement on the Department of Health and Human Services’ proposal requiring drug companies to disclose the list price of prescription drugs in television ads: “We share the Administration’s goal of reducing prescription drug prices. Pharmacy benefit managers (PBMs) foster competition among drugmakers, resulting

PCMA applauds the Administration for passing “lowest price acts”

PCMA applauds the Administration for passing “lowest price acts”

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. “PCMA strongly supports S. 2553 and S. 2554, legislation that will help ensure America’s patients always pay the lowest cost for their medications at

PCMA applauds passage of Bill to fight opioid epidemic

PCMA applauds passage of Bill to fight opioid epidemic

WASHINGTON — Today, the U.S. House of Representatives passed the SUPPORT for Patients and Communities Act (H.R. 6), which will require electronic prescribing (e-prescribing) for controlled substances in Medicare. This is a significant step in the fight against America’s opioid epidemic, the Pharmaceutical Care Management Association (PCMA) said. “This will save lives and reduce fraud by

PCMA supports legislation for lowest prices for prescription drugs

PCMA supports legislation for lowest prices for prescription drugs

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP): “PCMA strongly supports S. 2554, legislation that will ensure America’s

PCMA issues statement on FDA biosimilar action plan

PCMA issues statement on FDA biosimilar action plan

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on the Food and Drug Administration’s (FDA) new Biosimilars Action Plan: “We applaud the FDA for taking important steps toward approving more biosimilars in the United States. We are encouraged the FDA has designed a system that allows manufacturers

PCMA issues statement on the Administration’s Blueprint on drug pricing

PCMA issues statement on the Administration’s Blueprint on drug pricing

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement today on the Administration’s Blueprint on drug pricing: “We are encouraged that the Administration’s Blueprint raises several proposals that would increase the use of pharmacy benefit management (PBM) tools to reduce costs in public programs. We support using PBM tools